White paper on expanding the role of pharmacists in chronic obstructive pulmonary disease

Journal of the American Pharmacists Association

Volumn 51, Issue 2, 2011, Pages 203-211

  Brown, Peggy ^a   Kritzler, Robert ^b   Petryna, Michael ^c   Polley, Catherine M ^d   Tietze, Karen J ^e   Binaso, Kristen A ^f   Watson, Lindsay ^g   Ellis, William M ^h   Bluml, Benjamin M ^h   Cummings, Jim ⁱ   Sullivan, Marc ⁱ   Fitch, Mare Lynn ⁱ   Belknap, Bob ⁱ  

^a National Bronchiectasis Research Registry   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c AETNA   (United States)

^d Food Marketing Institute   (United States)

^e UNIVERSITY OF THE SCIENCES   (United States)

^f AMERICAN PHARMACISTS ASSOCIATION   (United States)

^g RUTGERS UNIVERSITY   (United States)

^h APhA Foundation   (United States)

ⁱ BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

American pharmacists association foundation; Chronic obstructive pulmonary disease; Collaborative practice; Medication therapy management; Pharmacy services

Indexed keywords

BRONCHODILATING AGENT;

CAUSE OF DEATH; CHRONIC OBSTRUCTIVE LUNG DISEASE; COST OF ILLNESS; COUGHING; DYSPNEA; EDUCATION PROGRAM; EMPLOYER; HEALTH SURVEY; HOSPITAL INFORMATION SYSTEM; HUMAN; INHALER; INTERHOSPITAL COOPERATION; LONG TERM CARE; MEDICAL INFORMATICS; MEDICATION COMPLIANCE; MEDICATION THERAPY MANAGEMENT; NEEDS ASSESSMENT; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT EDUCATION; PATIENT MONITORING; PHARMACIST; PHARMACIST ATTITUDE; PHYSICIAN; REIMBURSEMENT; REVIEW; SELF CARE; SMOKING CESSATION PROGRAM; SPIROMETRY; SPUTUM; SUPPORT GROUP; UNITED STATES; ADULT; ARTICLE; COOPERATION; HEALTH CARE ORGANIZATION; ORGANIZATION AND MANAGEMENT; PHARMACY; PROFESSIONAL STANDARD;

ADULT; COOPERATIVE BEHAVIOR; HUMANS; PHARMACEUTICAL SERVICES; PHARMACISTS; PROFESSIONAL ROLE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SOCIETIES, PHARMACEUTICAL; UNITED STATES;

EID: 79959501408     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1331/JAPhA.2011.11513     Document Type: Article

References (23)

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. Washington, DC: Medical Communications, Inc.; 2009.
2. National Heart, Lung, and Blood Institute. Morbidity and mortality 2007 chartbook on cardiovascular, lung, and blood disease. Bethesda, MD: National Heart, Lung, and Blood Institute; 2009.
3. Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United States, 1970-2002. JAMA. 2005;294:1255-9.
4. Grady D. From smoking boom, a major killer of women. Accessed at www.nytimes.com/2007/11/29/health/29lung.html?-r=1&oref.slogin, January 4, 2011.
5. Centers for Disease Control and Prevention. Chronic obstructive pulmonary disease (COPD). Accessed at www.cdc.gov/copd, January 4, 2011.
6. Mannino DM, Homa DM, Akinbami LJ, et al. Chronic obstructive pulmonary disease surveillance: United States, 1971-2000. Accessed at www.cdc.gov/mmwr/ preview/mmwrhtml/ss5106a1.htm, January 4, 2011.
7. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society Statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2003;168:818-900.
8. Fink JB, Rubin BK. Problems with inhaler use: a call for improved clinician and patient education. Respir Care. 2005;50:1360-74.
9. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487-97.
10. National Council on Patient Information and Education. Enhancing prescription medicine adherence: a national action plan. Accessed at www.talkaboutrx.org/documents/enhancing-prescription-medicine-adherence.pdf, January 4, 2011.
11. World Health Organization. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization; 2003.
12. Parkes G, Greenhalgh T, Griffin M, Dent R. Effect on smoking quit rate of telling patients their lung age: the Step2quit randomised controlled trial. BMJ. 2008;336:598-600.
13. American Pharmacists Association, National Assocation of Chain Drug Stores Foundation. Medication therapy management in pharmacy practice: core elements of an MTM service model (version 2.0). J Am Pharm Assoc. 2008;48:341-53.
14. Millonig MK. Mapping the route to medication therapy management documentation and billing standardization and interoperability within the health care system: meeting proceedings. J Am Pharm Assoc. 2009;49:372-82.
15. Bluml BM, McKenney JM, Cziraky MJ. Pharmaceutical care services and results in Project ImPACT: Hyperlipidemia. J Am Pharm Assoc. 2000;40:157-65.
16. Cranor CW, Bunting BA, Christensen DB. The Asheville Project: long-term clinical and economic outcomes of community pharmacy diabetes care program. J Am Pharm Assoc. 2003;43:173-84.
17. Bunting BA, Smith BH, Sutherland SE. The Asheville Project: clinical and economic outcomes of a community-based long-term medication therapy management program for hypertension and dyslipidemia. J Am Pharm Assoc. 2008;48:23-31.
18. Goode JV, Swiger K, Bluml BM. Regional osteoporosis screening, referral, and monitoring program in community pharmacies: findings from Project ImPACT: Osteoporosis. J Am Pharm Assoc. 2004;44:152-60.
19. Garrett DG, Bluml BM. Patient self-management program for diabetes: first-year clinical, humanistic, and economic outcomes. J Am Pharm Assoc. 2005;45:130-7.
20. Fera T, Bluml BM, Ellis WM, et al. The Diabetes Ten City Challenge: interim clinical and humanistic outcomes of a multisite community pharmacy diabetes care program. J Am Pharm Assoc. 2008;48:181-90.
21. Porter ME, Teisberg EO. Redefining health care frequently asked questions. Boston: Harvard Business School Publishing; 2006.
22. Gauthier A, Schoenbaum SC, Weinbaum I. Toward a high performance health system for the United States. New York: Commonwealth Fund; 2006.
23. Wagner EH, Austin BT, Davis C, et al. Improving chronic illness care: translating evidence into action. Health Aff (Millwood). 2001;20:64-78.